Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Holdings Lowered by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lowered its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 3.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 470,361 shares of the company’s stock after selling 18,801 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.15% of Amneal Pharmaceuticals worth $3,725,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter valued at approximately $81,000. Quest Partners LLC acquired a new stake in Amneal Pharmaceuticals during the 3rd quarter valued at $84,000. Cibc World Markets Corp acquired a new stake in shares of Amneal Pharmaceuticals in the fourth quarter worth $118,000. Janney Montgomery Scott LLC purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at $121,000. Finally, Fox Run Management L.L.C. raised its position in Amneal Pharmaceuticals by 69.0% during the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company’s stock valued at $162,000 after buying an additional 8,342 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $8.27 on Friday. The firm has a market cap of $2.56 billion, a PE ratio of -12.16 and a beta of 1.05. The firm’s 50 day moving average price is $8.42 and its 200 day moving average price is $8.37. Amneal Pharmaceuticals, Inc. has a twelve month low of $5.18 and a twelve month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03). The business had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter last year, the company earned $0.14 EPS. On average, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AMRX has been the subject of a number of research reports. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $9.00 to $12.00 in a research report on Monday, February 24th. Finally, Barclays increased their target price on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $10.80.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the transaction, the director now owns 1,808,886 shares of the company’s stock, valued at $16,099,085.40. This trade represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company’s stock, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 5,240,000 shares of company stock worth $43,754,000 over the last three months. Corporate insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.